External
Around the Helix: Cell and Gene Therapy Company Updates – May 27, 2026
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Source: CGTLive
Read more →News
What is happening at Brilliant Blue — and around it
Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
External
Wacker adds research services for nucleic-acid therapeutics
Wacker is expanding contract research to include RNA and plasmid construct design alongside its existing RNA, pDNA and LNP formulation activities. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →External
Around the Helix: Cell and Gene Therapy Company Updates – May 20, 2026
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Source: CGTLive
Read more →External
ASGCT 2026: GS-100 Gene Therapy Demonstrates Early Activity in NGLY1 Deficiency
New interim ASGCT 2026 findings suggest investigational AAV9 gene therapy GS-100 may improve motor and cognitive outcomes in children with NGLY1 Deficiency, while informing dose optimization and immune management strategies.
Source: CGTLive
Read more →External
Around the Helix: Cell and Gene Therapy Company Updates – May 13, 2026
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Source: CGTLive
Read more →External
Cellares and ProTgen plan automated ProT-096 manufacture
The collaboration covers production and quality control of a personalised progenitor T-cell therapy being developed for blood cancers. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →External
ETX101 Gene Therapy Shows Early Developmental, Seizure Benefits in Dravet Syndrome
New ASGCT 2026 data suggest Encoded Therapeutics’ investigational gene therapy ETX101 may meaningfully reduce seizures and alter developmental trajectory in children with SCN1A-positive Dravet syndrome.
Source: CGTLive
Read more →External
ParcelBio launches a programmable mRNA platform
ParcelBio announced a programmable mRNA platform and $13 million in financing for its emerging therapeutic pipeline. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →External
Cellular Origins and Immatics explore manufacturing automation
The collaborators will examine how automation could make cell-therapy production more efficient and scalable. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →External
Novelty Nobility extends its AGC manufacturing agreement
The companies are moving a candidate toward GMP manufacturing after cell-line development, with technology transfer planned between sites. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →External
Figurate launches a SCADA system for biopharma production
The company's newly announced control system emphasises instrument integration and real-time manufacturing oversight. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →External
Nonviral gene delivery moves toward translation
GEN reviews the translation of nonviral gene-delivery platforms, including lipid and polymer-based approaches. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.